|
|
Article: Biotech Holdings private placement funding to be applied to diabetes drug launch.
- Article from:
- Biotech Business Week
- Article date:
- November 22, 2004
CopyrightCOPYRIGHT 2004 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
2004 NOV 22 - (NewsRx.com & NewsRx.net) -- Robert Rieveley, president of Biotech Holdings (BIO.V; BIOHF) announced that the company has received preliminary regulatory approval to proceed with raising private placement funding totaling CDN $1,000,000.
"These funds will be applied to requirements associated with the launch of our diabetes drug, Sucanon, in Mexico including purchase of television and radio time, in-store support for Sucanon and medical presentations," Rieveley said.
"We have to date received $111,000 of the above private placement funding. Shares pursuant to this funding will be issued at $.50 Cdn, with each share having a 2-year warrant ...